Gynecological malignancies and hormonal therapies: Clinical management and recommendations

Table 1 Epithelial ovarian cancer

Ref.	Study design	HRT vs control	Stage	Type of HRT	Months HRT	Months follow up	Recurrence HRT vs controls	Study conclusions
Eeles et al[37]	Retrospective case-control	78/295	1-2: 55% 3-4: 45%	Oral Estrogen	Median 28	Median 42	-	No effects of HRT on prognosis
				Estrogen + Progestogen
				Estrogen + Tibolone
Guidozzi et al[12]	Randomized controlled trial	59/66	1-2: 27% 3-4: 73%	Conjugate Estrogen	28	Mean 42	32 vs 41	No effect of HRT on DFS and OFS
Bebar et al[36]	Retrospective cohort study	31/0	NS	Non-conjugated-Estrogen + Progestogen	Mean 25	Mean 55	3	No effect of HRT on progression of EOC
Ursic-Vrscaj et al[38]	Retrospective case-control	24/48	1-2: 54% 3-4: 46%	Non-conjugated-Estrogen	Mean 24	Mean 49	5 vs 15	No effect of HRT on survival
				Estrogen + Progestogen
				Estrogen + Tibolone
Mascarenhas et al[33]	Prospective cohort study	649 EOC	1-2: 60% 3-4: 40%	Estrogen	Up to 24	60	-	Better survival in HRT users vs non users
		150 BOT		Estrogen + Progestogen
Li et al[39]	Prospective cohort study	31/45	1-2: 28% 3-4: 72%	Conjugated-Estrogen + Progestogen	Mean 28.7	Mean 31.4	-	No effect of HRT on cumulative survival HRT improve quality of life

HRT: Hormone replacement therapy; EOC: Epithelial ovarian cancer; NS: Not specified; BOT: Borderline ovarian tumor; DFS: Disease free survival; OFS: Overall free survival.